Molineaux Christopher P. 4
4 · Aclaris Therapeutics, Inc. · Filed Jun 20, 2023
Insider Transaction Report
Form 4
Molineaux Christopher P.
Director
Transactions
- Exercise/Conversion
Common Stock
2023-06-15$1.52/sh+198$301→ 32,003 total - Exercise/Conversion
Stock Option (right to buy)
2023-06-15−51→ 0 totalExercise: $0.72Exp: 2024-08-12→ Common Stock (51 underlying) - Exercise/Conversion
Common Stock
2023-06-15$0.72/sh+51$37→ 31,805 total - Exercise/Conversion
Stock Option (right to buy)
2023-06-15−198→ 0 totalExercise: $1.52Exp: 2024-12-07→ Common Stock (198 underlying)
Footnotes (2)
- [F1]25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.
- [F2]25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.